key: cord-0805348-0vj9ykj1
authors: Jiang, Jipin; Miao, Yan; Zhao, Yuanyuan; Lu, Xia; Zhou, Ping; Zhou, Xiaojun; Chen, Zhishui; Du, Dunfeng
title: Convalescent Plasma Therapy: Helpful Treatment of COVID‐19 in a Kidney Transplant Recipient presenting with serve clinical manifestation and complex complications
date: 2020-06-30
journal: Clin Transplant
DOI: 10.1111/ctr.14025
sha: 1495c3d9b8a497214bbeb43f704957ffe8b7fa19
doc_id: 805348
cord_uid: 0vj9ykj1

The latest study observed that KTRs with COVID‐19 had a higher early mortality than persons with COVID‐19 in the general population([1]). To date, there is no specific drugs. Previous studies showed convalescent plasma could help patient recovery from SARS([2, 3]). However, only a very limit evidences has been showed it is effective in COVID‐19 treatment([4, 5]). Here, we describe the first successful recovery of case of COVID‐19 in a KTR treated with convalescent plasma therapy.

Computed tomography 

This article is protected by copyright. All rights reserved Dear Editor,

The latest study observed that KTRs with COVID-19 had a higher early mortality than persons with COVID-19 in the general population [1] . To date, there is no specific drugs. Previous studies showed convalescent plasma could help patient recovery from SARS [2, 3] . However, only a very limit evidences has been showed it is effective in COVID-19 treatment [4, 5] .

Here, we describe the first successful recovery of case of COVID-19 in a KTR treated with convalescent plasma therapy. The 70-year-old woman underwent a brain death donor kidney transplantation 10 years ago, with a history of chronic bronchitis, hypertension, and hyperlipidemia. Her current immunosuppression was CsA (50 mg bid), MMF (500 mg bid), and Pred (5 mg qd). On January 25, 2020 (day 1 of illness), the patient showed initial symptoms of cough without fever or asthma (timeline of the illness course was shown in Fig. 1 ). Due to a propensity to cough in winter, she took cefdinir tablets 100mg tid for 7 days by herself. However, fever occurred on day 20, with a maximum temperature of 38.2 °C. When she visited a fever clinic for treatment, the laboratory investigations were as follows: SpO 2 of 90%, WBC=20.38×10 9 /L, Scr=236.5 μmol/L (eGFR of 17.6 ml/min/1.73m 2 ), and CRP=16.7 mg/L. The oropharyngeal swab tested positive for SARS-CoV-2. The chest CT showed increased texture, and mixed diffuse GGO in both lungs with linear grid shadows in between (Fig 2A) . Immediately, CsA was discontinued, 

in the left lower limb. Therefore, symptomatic support treatment was immediately administered.

On day 52, 'the chest CT was significantly better than at admission (Fig 2B) . Therefore, the patient was discharged. On her 14 day of isolation, the chest CT was better than before. In addition, we tested the serum IgM and total antibodies of SARS-CoV-2 recently (on Apr. 22, 2020). The results showed that the total antibody of SARS-CoV-2 was significantly increased to 265.96 COI (normal range: 0-1 COI).

Altogether, insidious onset, serve clinical manifestation and complex complications including fungal infection, and lower limb vein thrombosis was occurred in this elder patient. Management of immunosuppressive agents were dynamically adjusted according to pathogenetic condition in order to establish the equipoise between infection and rejection. In addition, it's worth noting that the patient had an older age and underlying cardiovascular diseases, which were associated with severe clinical symptoms and poor prognosis [6] . Therefore, the use of plasma was helpful for SARS-CoV-2 clearance and patient recovery.

Covid-19 and Kidney Transplantation

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Convalescent plasma as a potential therapy for COVID-19

Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea

A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals

Characteristics of and Important Lessons From the Coronavirus

This work was supported by the Science and Technology Foundation of Hubei Province (2018CFB554 and 2019CFB659) and the National Natural Science Foundation of China (No. 81700300).

All authors of this manuscript declare that no conflicts of interest.

No organs from executed prisoners were used in the manuscript.